zovaglutide + metformin + warfarin

ZT002 + metformin + warfarin refers to the co-administration of zovaglutide (ZT002), metformin, and warfarin within a clinical trial setting. **Zovaglutide** is a novel, ultra long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) developed by Beijing QL Biopharmaceutical for the treatment of obesity and type 2 diabetes mellitus. It is a peptide biologic designed for once-monthly or biweekly subcutaneous administration. **Metformin** is a biguanide antihyperglycemic agent that primarily acts by activating AMP-activated protein kinase (AMPK) and inhibiting hepatic gluconeogenesis. **Warfarin** is a vitamin K antagonist anticoagulant that inhibits the vitamin K epoxide reductase complex. This specific combination was evaluated in a Phase 1, open-label, two-period crossover drug-drug interaction (DDI) study to assess the impact of multiple subcutaneous injections of zovaglutide on the pharmacokinetics of metformin and warfarin (acting as probe substrates) in overweight and obese participants.

Other names

ZT002 + metformin + warfarin